Science Explorer Interactive view Map
Company · River Forest · United States

CDG Therapeutics (United States)

cdgti.comROR OpenAlex
Research works
28
▲ 9% vs 2013–17
Citations
305
10.8 per fractional work
Top-10% rate
16.7%
record average 16.5%
Open access
35%
world 28%

Not ranked overall: CDG Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 0.87× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 13.73× its world share, 1 worksImmunology and Micro…Neuroscience: 0.70× its world share, 0 worksNeuroscienceChemistry: 0.97× its world share, 0 worksChemistryMathematics: 1.23× its world share, 0 worksMathematicsHealth Professions: 3.09× its world share, 1 worksHealth ProfessionsMedicine: 3.56× its world share, 5 worksMedicineEconomics, Econometrics and Finance: 0.43× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 13.7×. Every wedge is a field page.

Who are the top researchers at CDG Therapeutics (United States)?

Ranked on the composite score, Michael Weiss, Emmanuel Normant and Peter Sportelli lead among researchers whose main affiliation is CDG Therapeutics (United States).

  1. 1 Michael Weiss United States · #131,051 worldwide 128 citations · 45 works
  2. 2 Emmanuel Normant United States · #557,974 worldwide 76 citations · 16 works
  3. 3 Peter Sportelli United States · #868,526 worldwide 18 citations · 15 works
All ranked researchers at CDG Therapeutics (United States)

Which keywords describe research at CDG Therapeutics (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Rituximab, Prognostic Factors, Therapeutic Targets, Chronic Lymphocytic Leukemia, Genomic Aberrations, Lymphoma, PET Imaging and Classification.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 18 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 18 words, with their numbers
  1. Rituximab10▲ 218×2 topics
  2. Prognostic Factors7▲ 56×6 topics
  3. Therapeutic Targets6▲ 89×2 topics
  4. Chronic Lymphocytic Leukemia6▲ 425×1 topic
  5. Genomic Aberrations6▲ 425×1 topic
  6. Lymphoma5▲ 111×3 topics
  7. PET Imaging4▲ 71×4 topics
  8. Classification4▲ 39×2 topics
  9. Genetic Pathogenesis4▲ 235×1 topic
  10. Molecular Profiling4▲ 119×1 topic
  11. Glycosylation2▲ 40×3 topics
  12. Monoclonal Antibodies2▲ 56×2 topics
  13. Fc Receptors2▲ 63×1 topic
  14. Therapeutic Antibodies2▲ 49×1 topic
  15. Cancer1▲ 3.3×5 topics
  16. Cancer Immunotherapy1▲ 33×3 topics
  17. Breast Cancer1▲ 16×2 topics
  18. Immunotherapy1▲ 5.9×4 topics

Which research topics does CDG Therapeutics (United States) publish most on?

By volume in 2022–2025: Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Safe Handling of Antineoplastic Drugs and Biosimilars and Bioanalytical Methods.

Chronic Lymphocytic Leuk…1Chronic Lymphocytic Leukemia Research: 1 fractional worksLymphoma Diagnosis and T…1Lymphoma Diagnosis and Treatment: 1 fractional worksSafe Handling of Antineoplastic Drugs: 0 fractional worksBiosimilars and Bioanalytical Methods: 0 fractional worksMultiple Sclerosis Research Studies: 0 fractional worksMonoclonal and Polyclona…0Monoclonal and Polyclonal Antibodies Research: 0 fractional worksCAR-T cell therapy research: 0 fractional worksAcute Lymphoblastic Leukemia research: 0 fractional worksCutaneous lymphoproliferative disorders research: 0 fractional worksViral-associated cancers and disorders: 0 fractional works
GeneticsPathology and Forensic MedicineOccupational TherapyImmunology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Chronic Lymphocytic Leukemia Research Genetics 1 works
  2. 2 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 1 works
  3. 3 Safe Handling of Antineoplastic Drugs Occupational Therapy 0 works
  4. 4 Biosimilars and Bioanalytical Methods Immunology 0 works
  5. 5 Multiple Sclerosis Research Studies Pathology and Forensic Medicine 0 works
  6. 6 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  7. 7 CAR-T cell therapy research Oncology 0 works
  8. 8 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 0 works
  9. 9 Cutaneous lymphoproliferative disorders research Dermatology 0 works
  10. 10 Viral-associated cancers and disorders Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available35.0%not open65.0%

World: 28% of research is openly available.

with international co-authors38.2%domestic only61.8%

World: 19% is written across borders.

How has CDG Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 9% higher than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in River Forest

All research institutions in River Forest

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.